Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 20

1.

Educating the Next Generation of Peer Reviewers.

Cooper LB, Bellam N, Vaduganathan M; JACC: Heart Failure Fellows.

J Am Coll Cardiol. 2016 May 3;67(17):2079-82. doi: 10.1016/j.jacc.2016.03.483. No abstract available.

2.

Long-Term Prognosis After Coronary Artery Calcification Testing in Asymptomatic Patients: A Cohort Study.

Shaw LJ, Giambrone AE, Blaha MJ, Knapper JT, Berman DS, Bellam N, Quyyumi A, Budoff MJ, Callister TQ, Min JK.

Ann Intern Med. 2015 Jul 7;163(1):14-21. doi: 10.7326/M14-0612.

PMID:
26148276
3.

Team-Based Care for Managing Cardiac Comorbidities in Heart Failure.

Bellam N, Kelkar AA, Whellan DJ.

Heart Fail Clin. 2015 Jul;11(3):407-17. doi: 10.1016/j.hfc.2015.03.005.

PMID:
26142638
4.

Disseminated fusariosis during acute myelogenous leukemia induction treatment.

Mehta A, Bellam N.

Blood. 2014 May 29;123(22):3379. doi: http://dx.doi.org/10.1182/blood-2014-02-556654. No abstract available.

5.

Phase 1b study of otlertuzumab (TRU-016), an anti-CD37 monospecific ADAPTIR™ therapeutic protein, in combination with rituximab and bendamustine in relapsed indolent lymphoma patients.

Gopal AK, Tarantolo SR, Bellam N, Green DJ, Griffin M, Feldman T, Mato AR, Eisenfeld AJ, Stromatt SC, Goy A.

Invest New Drugs. 2014 Dec;32(6):1213-25. doi: 10.1007/s10637-014-0125-2. Epub 2014 Jun 15.

6.

Non-Hodgkin's lymphomas, version 2.2014.

Zelenetz AD, Gordon LI, Wierda WG, Abramson JS, Advani RH, Andreadis CB, Bartlett N, Bellam N, Byrd JC, Czuczman MS, Fayad LE, Fisher RI, Glenn MJ, Harris NL, Hoppe RT, Horwitz SM, Kelsey CR, Kim YH, Krivacic S, LaCasce AS, Nademanee A, Porcu P, Press O, Rabinovitch R, Reddy N, Reid E, Sokol L, Swinnen LJ, Tsien C, Vose JM, Yahalom J, Zafar N, Dwyer M, Sundar H.

J Natl Compr Canc Netw. 2014 Jun;12(6):916-46.

PMID:
24925202
7.

Prognostic significance of calcified plaque among symptomatic patients with nonobstructive coronary artery disease.

Shah S, Bellam N, Leipsic J, Berman DS, Quyyumi A, Hausleiter J, Achenbach S, Al-Mallah M, Budoff MJ, Cademartiri F, Callister TQ, Chang HJ, Chow BJ, Cury RC, Delago AJ, Dunning AL, Feuchtner GM, Hadamitzky M, Karlsberg RP, Kaufmann PA, Lin FY, Chinnaiyan KM, Maffei E, Raff GL, Villines TC, Gomez MJ, Min JK, Shaw LJ; CONFIRM (COronary CT Angiography EvaluatioN For Clinical Outcomes: An InteRnational Multicenter Registry) Investigators.

J Nucl Cardiol. 2014 Jun;21(3):453-66. doi: 10.1007/s12350-014-9865-9. Epub 2014 Mar 29.

8.

Prognostic significance of impaired chronotropic response to pharmacologic stress Rb-82 PET.

Bellam N, Veledar E, Dorbala S, Di Carli MF, Shah S, Eapen D, Quyyumi A, Beanlands RS, Merhige ME, Williams BA, Chow BJ, Min JK, Berman DS, Shaw LJ.

J Nucl Cardiol. 2014 Apr;21(2):233-44. doi: 10.1007/s12350-013-9820-1. Epub 2014 Jan 31.

PMID:
24482141
9.

Influence of race/ethnic differences in pre-transplantation panel reactive antibody on outcomes in heart transplant recipients.

Morris AA, Cole RT, Veledar E, Bellam N, Laskar SR, Smith AL, Gebel HM, Bray RA, Butler J.

J Am Coll Cardiol. 2013 Dec 17;62(24):2308-15. doi: 10.1016/j.jacc.2013.06.054. Epub 2013 Aug 28.

10.

Influence of sex on risk stratification with stress myocardial perfusion Rb-82 positron emission tomography: Results from the PET (Positron Emission Tomography) Prognosis Multicenter Registry.

Kay J, Dorbala S, Goyal A, Fazel R, Di Carli MF, Einstein AJ, Beanlands RS, Merhige ME, Williams BA, Veledar E, Chow BJ, Min JK, Berman DS, Shah S, Bellam N, Butler J, Shaw LJ.

J Am Coll Cardiol. 2013 Nov 12;62(20):1866-76. doi: 10.1016/j.jacc.2013.06.017. Epub 2013 Jul 10.

11.

Polypill strategy for primary prevention of cardiovascular disorders.

Dabhadkar KC, Bellam N.

Drugs Today (Barc). 2013 May;49(5):317-24. doi: 10.1358/dot.2013.49.5.1950148. Review.

PMID:
23724411
12.

Non-Hodgkin's lymphomas, version 1.2013.

Zelenetz AD, Wierda WG, Abramson JS, Advani RH, Andreadis CB, Bartlett N, Bellam N, Byrd JC, Czuczman MS, Fayad LE, Glenn MJ, Gockerman JP, Gordon LI, Harris NL, Hoppe RT, Horwitz SM, Kelsey CR, Kim YH, Krivacic S, LaCasce AS, Nademanee A, Porcu P, Press O, Pro B, Reddy N, Sokol L, Swinnen L, Tsien C, Vose JM, Yahalom J, Zafar N, Dwyer MA, Naganuma M; National Comprehensive Cancer Network.

J Natl Compr Canc Netw. 2013 Mar 1;11(3):257-72; quiz 273.

PMID:
23486452
13.

Non-Hodgkin's Lymphomas, version 3.2012.

Zelenetz AD, Wierda WG, Abramson JS, Advani RH, Andreadis CB, Bartlett N, Bellam N, Byrd JC, Czuczman MS, Fayad L, Glenn MJ, Gockerman JP, Gordon LI, Harris NL, Hoppe RT, Horwitz SM, Kelsey CR, Kim YH, Krivacic S, LaCasce AS, Nademanee A, Porcu P, Press O, Pro B, Reddy N, Sokol L, Swinnen L, Tsien C, Vose JM, Yahalom J, Zafar N, Naganuma M, Dwyer MA.

J Natl Compr Canc Netw. 2012 Dec 1;10(12):1487-98.

PMID:
23221787
14.

Acute lymphoblastic leukemia.

Alvarnas JC, Brown PA, Aoun P, Ballen KK, Bellam N, Blum W, Boyer MW, Carraway HE, Coccia PF, Coutre SE, Cultrera J, Damon LE, DeAngelo DJ, Douer D, Frangoul H, Frankfurt O, Goorha S, Millenson MM, O'Brien S, Petersdorf SH, Rao AV, Terezakis S, Uy G, Wetzler M, Zelenetz AD, Naganuma M, Gregory KM; National Comprehensive Cancer Network.

J Natl Compr Canc Netw. 2012 Jul 1;10(7):858-914.

PMID:
22773801
15.

Non-Hodgkin's lymphomas.

Zelenetz AD, Abramson JS, Advani RH, Andreadis CB, Bartlett N, Bellam N, Byrd JC, Czuczman MS, Fayad LE, Glenn MJ, Gockerman JP, Gordon LI, Harris NL, Hoppe RT, Horwitz SM, Kelsey CR, Kim YH, LaCasce AS, Nademanee A, Porcu P, Press O, Pro B, Reddy N, Sokol L, Swinnen LJ, Tsien C, Vose JM, Wierda WG, Yahalom J, Zafar N.

J Natl Compr Canc Netw. 2011 May;9(5):484-560. No abstract available.

PMID:
21550968
16.

Tgf-beta signaling alterations and colon cancer.

Bellam N, Pasche B.

Cancer Treat Res. 2010;155:85-103. doi: 10.1007/978-1-4419-6033-7_5. Review.

PMID:
20517689
17.

Constitutively decreased TGFBR1 allelic expression is a common finding in colorectal cancer and is associated with three TGFBR1 SNPs.

Pasche B, Wisinski KB, Sadim M, Kaklamani V, Pennison MJ, Zeng Q, Bellam N, Zimmerman J, Yi N, Zhang K, Baron J, Stram DO, Hayes MG.

J Exp Clin Cancer Res. 2010 May 25;29:57. doi: 10.1186/1756-9966-29-57.

18.

14-3-3Tau regulates ubiquitin-independent proteasomal degradation of p21, a novel mechanism of p21 downregulation in breast cancer.

Wang B, Liu K, Lin HY, Bellam N, Ling S, Lin WC.

Mol Cell Biol. 2010 Mar;30(6):1508-27. doi: 10.1128/MCB.01335-09. Epub 2010 Jan 19.

19.

Regulation of p53 by TopBP1: a potential mechanism for p53 inactivation in cancer.

Liu K, Bellam N, Lin HY, Wang B, Stockard CR, Grizzle WE, Lin WC.

Mol Cell Biol. 2009 May;29(10):2673-93. doi: 10.1128/MCB.01140-08. Epub 2009 Mar 16.

20.

Strategies to enhance patient adherence: making it simple.

Atreja A, Bellam N, Levy SR.

MedGenMed. 2005 Mar 16;7(1):4.

Supplemental Content

Loading ...
Support Center